Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?

Gosset M, Chargari C, Bentivegna E, Leary A, Genestie C, Maulard A, Morice P, Gouy S.

Anticancer Res. 2019 Jun;39(6):2919-2926. doi: 10.21873/anticanres.13421.

PMID:
31177130
2.

Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers.

Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Daraï E, Chabbert-Buffet N, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, Thibault MR, Ferron G, Devouassoux M, Kurtz JE, Provansal M, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I.

Eur J Cancer. 2019 Jul;116:35-44. doi: 10.1016/j.ejca.2019.04.018. Epub 2019 Jun 3.

PMID:
31170563
3.

Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer.

Peters EEM, Bartosch C, McCluggage WG, Genestie C, Lax SF, Nout R, Oosting J, Singh N, Smit HCSH, Smit VTHBM, Van de Vijver KK, Bosse T.

Histopathology. 2019 Jul;75(1):128-136. doi: 10.1111/his.13871. Epub 2019 Jun 10.

PMID:
31155736
4.

Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation.

Poirot C, Fortin A, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Brice P, Morice P, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Gouy S, Chalas C, Egels S, Dhédin N, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N; CAROLéLISA Cooperative Group.

Hum Reprod. 2019 Jun 4;34(6):1083-1094. doi: 10.1093/humrep/dez047.

PMID:
31116405
5.

[SCCOHT/ovarian rhabdoid tumor: A case report].

Bourgoin R, Cornelis F, Masliah-Planchon J, Genestie C, Laé M.

Ann Pathol. 2019 Mar 27. pii: S0242-6498(19)30040-9. doi: 10.1016/j.annpat.2019.02.005. [Epub ahead of print] French.

PMID:
30928254
6.

Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type.

Gouy S, Saidani M, Maulard A, Bach-Hamba S, Bentivegna E, Leary A, Pautier P, Devouassoux-Shisheboran M, Genestie C, Morice P.

Int J Gynecol Cancer. 2018 Mar;28(3):493-499. doi: 10.1097/IGC.0000000000001202.

PMID:
30814210
7.

Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies.

Poirot C, Fortin A, Dhédin N, Brice P, Socié G, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Chalas C, Egels S, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N.

Haematologica. 2019 Aug;104(8):e360-e363. doi: 10.3324/haematol.2018.211094. Epub 2019 Feb 14. No abstract available.

8.

Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.

Gouy S, Arfi A, Maulard A, Pautier P, Bentivegna E, Leary A, Chargari C, Genestie C, Morice P.

Oncologist. 2019 May;24(5):702-709. doi: 10.1634/theoncologist.2017-0632. Epub 2018 Sep 10.

PMID:
30201740
9.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

PMID:
29955143
10.

Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery.

Perrin M, Bentivegna E, Bonneau C, Uzan C, Leary A, Pautier P, Genestie C, Morice P, Gouy S.

Anticancer Res. 2018 Apr;38(4):2247-2252.

PMID:
29599346
11.

Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience.

Castelnau-Marchand P, Pautier P, Genestie C, Leary A, Bentivegna E, Gouy S, Scoazec JY, Morice P, Haie-Meder C, Chargari C.

Int J Gynecol Cancer. 2018 Jun;28(5):1013-1019. doi: 10.1097/IGC.0000000000001242.

PMID:
29595759
12.

Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer.

Canlorbe G, Touboul C, Chargari C, Bentivegna E, Maulard A, Pautier P, Genestie C, Morice P, Gouy S.

Anticancer Res. 2018 Mar;38(3):1517-1523.

PMID:
29491080
13.

Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type.

Gouy S, Saidani M, Maulard A, Bach-Hamba S, Bentivegna E, Leary A, Pautier P, Devouassoux-Shisheboran M, Genestie C, Morice P.

Int J Gynecol Cancer. 2018 Mar;28(3):493-499. doi: 10.1097/IGC.0000000000001202.

PMID:
29466254
14.

Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration.

Muller M, Guillaud-Bataille M, Salleron J, Genestie C, Deveaux S, Slama A, de Paillerets BB, Richard S, Benusiglio PR, Ferlicot S.

Mod Pathol. 2018 Jun;31(6):974-983. doi: 10.1038/s41379-018-0017-7. Epub 2018 Feb 6.

15.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I.

Bull Cancer. 2018 Mar;105(3):299-314. doi: 10.1016/j.bulcan.2017.10.032. French.

PMID:
29397916
16.

[Erratum to: "Histological and molecular classification of endometrial carcinoma and therapeutical implications" [Bull. Cancer 104 (2017) 1001-1012]].

Genestie C, Leary A, Devouassoux M, Auguste A.

Bull Cancer. 2018 Feb;105(2):214. doi: 10.1016/j.bulcan.2017.12.002. Epub 2018 Feb 1. French. No abstract available.

PMID:
29395040
17.

Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.

Croce S, Ducoulombier A, Ribeiro A, Lesluyes T, Noel JC, Amant F, Guillou L, Stoeckle E, Devouassoux-Shisheboran M, Penel N, Floquet A, Arnould L, Guyon F, Mishellany F, Chakiba C, Cuppens T, Zikan M, Leroux A, Frouin E, Farre I, Genestie C, Valo I, MacGrogan G, Chibon F.

Mod Pathol. 2018 May;31(5):816-828. doi: 10.1038/modpathol.2017.185. Epub 2018 Jan 12.

18.

Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers.

Gouy S, Saidani M, Maulard A, Bach-Hamba S, Bentivegna E, Leary A, Pautier P, Devouassoux-Shisheboran M, Genestie C, Morice P.

Oncologist. 2018 Mar;23(3):324-327. doi: 10.1634/theoncologist.2017-0310. Epub 2017 Dec 14.

19.

Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.

Khairallah AS, Genestie C, Auguste A, Leary A.

Int J Cancer. 2018 Jul 1;143(1):8-15. doi: 10.1002/ijc.31200. Epub 2017 Dec 23. Review.

20.

[Histological and molecular classification of endometrial carcinoma and therapeutical implications].

Genestie C, Leary A, Devouassoux M, Auguste A.

Bull Cancer. 2017 Dec;104(12):1001-1012. doi: 10.1016/j.bulcan.2017.08.004. Epub 2017 Oct 12. Review. French. Erratum in: Bull Cancer. 2018 Jan 30;:.

PMID:
29031505
21.

Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?

Gouy S, Saidani M, Maulard A, Faron M, Bach-Hamba S, Bentivegna E, Leary A, Pautier P, Devouassoux-Shisheboran M, Genestie C, Morice P.

Gynecol Oncol Rep. 2017 Sep 28;22:52-54. doi: 10.1016/j.gore.2017.09.011. eCollection 2017 Nov.

22.

Ovarian Cancer: A Heterogeneous Disease.

Kossaï M, Leary A, Scoazec JY, Genestie C.

Pathobiology. 2018;85(1-2):41-49. doi: 10.1159/000479006. Epub 2017 Oct 12.

23.

Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types.

Gouy S, Saidani M, Maulard A, Faron M, Bach-Hamba S, Bentivegna E, Leary A, Pautier P, Devouassoux-Shisheboran M, Genestie C, Morice P.

Gynecol Oncol Rep. 2017 Sep 1;22:21-25. doi: 10.1016/j.gore.2017.08.006. eCollection 2017 Nov.

24.

Cancers de l’ovaire BRCA muté : consultation d’oncogénétique et prescription des inhibiteurs de PARP.

Gladieff L, Lyonnet DS, Lortholary A, Leary A, Genestie C, Ray-Coquard I.

Bull Cancer. 2017 May;104 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(17)30158-3. French.

PMID:
28625311
25.

In vivo imaging of uterine cervix with a Mueller polarimetric colposcope.

Vizet J, Rehbinder J, Deby S, Roussel S, Nazac A, Soufan R, Genestie C, Haie-Meder C, Fernandez H, Moreau F, Pierangelo A.

Sci Rep. 2017 Jun 1;7(1):2471. doi: 10.1038/s41598-017-02645-9.

26.

Networking for ovarian rare tumors: a significant breakthrough improving disease management.

Chiannilkulchai N, Pautier P, Genestie C, Bats AS, Vacher-Lavenu MC, Devouassoux-Shisheboran M, Treilleux I, Floquet A, Croce S, Ferron G, Mery E, Pomel C, Penault-Llorca F, Lefeuvre-Plesse C, Henno S, Leblanc E, Lemaire AS, Averous G, Kurtz JE, Ray-Coquard I.

Ann Oncol. 2017 Jun 1;28(6):1274-1279. doi: 10.1093/annonc/mdx099.

PMID:
28398524
27.

Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.

Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, Slama A, Poulalhon N, Escudier B, Albiges L, Soufir N, Avril MF, Gardie B, Saldana C, Allory Y, Gimenez-Roqueplo AP, Bressac-de Paillerets B, Richard S, Benusiglio PR.

Clin Genet. 2017 Dec;92(6):606-615. doi: 10.1111/cge.13014. Epub 2017 May 2. Erratum in: Clin Genet. 2018 May;93(5):1118.

PMID:
28300276
28.

Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment.

Annede P, Gouy S, Mazeron R, Bentivegna E, Maroun P, Petit C, Dumas I, Leary A, Genestie C, Lhommé C, Deutsch E, Morice P, Pautier P, Haie-Meder C, Chargari C.

Oncologist. 2017 Feb;22(2):182-188. doi: 10.1634/theoncologist.2016-0204. Epub 2017 Feb 7.

29.

Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors.

Escande A, Gouy S, Mazeron R, Bentivegna E, Bacorro W, Maroun P, Schernberg A, Oberlander AS, Dumas I, Genestie C, Deutsch E, Morice P, Haie-Meder C, Chargari C.

Gynecol Oncol. 2017 Mar;144(3):541-546. doi: 10.1016/j.ygyno.2016.12.026. Epub 2017 Jan 15.

PMID:
28095994
30.

Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy.

Heudel PE, Devouassoux-Shisheboran M, Taieb S, Genestie C, Selle F, Morice P, Rouzier R, Ray-Coquard I.

Eur J Gynaecol Oncol. 2017;38(2):175-180. Review.

PMID:
29953774
31.

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).

Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, Pautier P, Michels J, Le Formal A, Cheaib B, Adam J, Leary AF.

Ann Oncol. 2017 Mar 1;28(3):651-657. doi: 10.1093/annonc/mdw625.

PMID:
27864219
32.

Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy.

Chargari C, Mazeron R, Dunant A, Gouy S, Petit C, Maroun P, Uzan C, Annede P, Bentivegna E, Balleyguier C, Genestie C, Pautier P, Leary A, Lhomme C, Deutsch E, Morice P, Haie-Meder C.

Clin Exp Metastasis. 2016 Dec;33(8):775-785. Epub 2016 Aug 16.

PMID:
27530648
33.

Post radiation hysterectomy in locally advanced cervical cancer: Outcomes and dosimetric impact.

Mazeron R, Gouy S, Chargari C, Rivin Del Campo E, Dumas I, Mervoyer A, Genestie C, Bentivegna E, Balleyguier C, Pautier P, Morice P, Haie-Meder C.

Radiother Oncol. 2016 Sep;120(3):460-466. doi: 10.1016/j.radonc.2016.07.010. Epub 2016 Aug 2.

PMID:
27492204
34.

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

de la Motte Rouge T, Pautier P, Genestie C, Rey A, Gouy S, Leary A, Haie-Meder C, Kerbrat P, Culine S, Fizazi K, Lhommé C.

Gynecol Oncol. 2016 Sep;142(3):452-7. doi: 10.1016/j.ygyno.2016.07.005. Epub 2016 Jul 8.

PMID:
27401840
35.

[Glandular lesions of the uterine cervix: Case 3].

Kossai M, Duvillard P, Genestie C.

Ann Pathol. 2016 Jun;36(3):188-91. doi: 10.1016/j.annpat.2016.03.004. Epub 2016 May 25. French. No abstract available.

PMID:
27236348
36.

[Glandular lesions of the uterine cervix: Case 4].

Genestie C, Kacem CH, Duvillard P.

Ann Pathol. 2016 Jun;36(3):192-4. doi: 10.1016/j.annpat.2016.03.001. Epub 2016 May 24. French. No abstract available.

PMID:
27234516
37.

Cytomorphology of ovarian clear cell carcinomas in peritoneal effusions.

Damiani D, Suciu V, Genestie C, Vielh P.

Cytopathology. 2016 Dec;27(6):427-432. doi: 10.1111/cyt.12297. Epub 2016 Mar 2.

PMID:
26932246
38.

[Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].

Devouassoux-Shisheboran M, Genestie C, Ray-Coquard I.

Bull Cancer. 2016 Mar;103(3):252-8. doi: 10.1016/j.bulcan.2015.12.005. Epub 2016 Feb 4. Review. French.

PMID:
26853278
39.

Growing teratoma syndrome of the ovary presenting with liver metastasis: report of a case.

Soufi M, Lupinacci RM, Godiris-Petit G, Vignot S, Genestie C, Menegaux F, Lefranc JP.

Eur J Gynaecol Oncol. 2015;36(4):473-6.

PMID:
26390706
40.

Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases.

Bentivegna E, Azaïs H, Uzan C, Leary A, Pautier P, Gonthier C, Genestie C, Balleyguier C, Lhomme C, Duvillard P, Morice P, Gouy S.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S964-70. doi: 10.1245/s10434-015-4608-y. Epub 2015 Jun 2.

PMID:
26033179
41.

[Initial management of advanced ovarian cancer: What radiological, pathological and surgical information are important for optimal therapeutic strategy?].

Heudel PE, Selle F, Morice P, Rouzier R, Taieb S, Devouassoux-Shisheboran M, Genestie C, Balleyguier C, Ray-Coquard I.

Bull Cancer. 2015 Sep;102(9):772-9. doi: 10.1016/j.bulcan.2015.04.011. Epub 2015 May 28. Review. French.

PMID:
26028492
42.

Gliomatosis peritonei: a particular entity with specific outcomes within the growing teratoma syndrome.

Bentivegna E, Gonthier C, Uzan C, Genestie C, Duvillard P, Morice P, Gouy S.

Int J Gynecol Cancer. 2015 Feb;25(2):244-9. doi: 10.1097/IGC.0000000000000345.

PMID:
25594144
43.

Pathobiology of ovarian carcinomas.

Devouassoux-Shisheboran M, Genestie C.

Chin J Cancer. 2015 Jan;34(1):50-5. doi: 10.5732/cjc.014.10273. Review.

44.

Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.

Thoury A, Descatoire V, Kotelevets L, Kannengiesser C, Bertrand G, Theou-Anton N, Frey C, Genestie C, Raymond E, Chastre E, Lehy T, Walker F.

Histol Histopathol. 2014 Nov;29(11):1455-66. doi: 10.14670/HH-29.1455. Epub 2014 May 8.

PMID:
24811063
45.

[Histology of bone metastases (technical aspects, searching for a primary)].

Larousserie F, Genestie C.

Bull Cancer. 2013 Nov;100(11):1101-8. doi: 10.1684/bdc.2013.1844. Review. French.

PMID:
24192153
46.

Mitosis detection in breast cancer histological images An ICPR 2012 contest.

Roux L, Racoceanu D, Loménie N, Kulikova M, Irshad H, Klossa J, Capron F, Genestie C, Le Naour G, Gurcan MN.

J Pathol Inform. 2013 May 30;4:8. doi: 10.4103/2153-3539.112693. Print 2013.

47.

[Gynecopathology. Case 6. Uterine tumors resembling ovarian sex cord tumor].

Genestie C, Finet JF, Vacher Lavenu MC.

Ann Pathol. 2012 Jun;32(3):206-10. doi: 10.1016/j.annpat.2012.04.006. Epub 2012 Jun 7. French. No abstract available.

PMID:
22748338
48.

[Gynecopathology. Case 5. Epithelioid smooth muscle tumors].

Genestie C, Devouassoux-Shisheboran M.

Ann Pathol. 2012 Jun;32(3):202-5. doi: 10.1016/j.annpat.2012.04.005. Epub 2012 Jun 8. French. No abstract available.

PMID:
22748337
49.

Pathology of endometrioid carcinoma.

Albertini AF, Devouassoux-Shisheboran M, Genestie C.

Bull Cancer. 2012 Jan;99(1):7-12. doi: 10.1684/bdc.2011.1526. Review.

50.

Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique.

Querleu D, Planchamp F, Narducci F, Morice P, Joly F, Genestie C, Haie-Meder C, Thomas L, Quénel-Tueux N, Daraï E, Dorangeon PH, Marret H, Taïeb S, Mazeau-Woynar V; Institut National du Cancer; Societe Francaise d'Oncologie Gynecologique.

Int J Gynecol Cancer. 2011 Jul;21(5):945-50. doi: 10.1097/IGC.0b013e31821bd473.

PMID:
21697683

Supplemental Content

Loading ...
Support Center